相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MCL-1 inhibits BAX in the absence of MCL-1/BAX interaction
Marc Germain et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells totreatment with gefitinib
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Myeloid cell leukemia-1 as a therapeutic target
Arthur M. Mandelin et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR)
Robert D. Hubbard et al.
CHEMMEDCHEM (2007)
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib
Christele Desbois-Mouthon et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Floriana Morgillo et al.
CANCER RESEARCH (2006)
Regulation of apoptosis by insulin-like growth factor (IGF)-I
Ron Kooijman
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH2-terminal kinase/activator protein-1 signaling to regulate cell migration
Xiaojiang Cui et al.
CANCER RESEARCH (2006)
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Rita Nahta et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
Cyclin D1: polymorphism, aberrant splicing and cancer risk
KE Knudsen et al.
ONCOGENE (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer
N Normanno et al.
GENE (2006)
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
RL Yauch et al.
CLINICAL CANCER RESEARCH (2005)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2005)
Location, location, location: The role of cyclin D1 nuclear localization in cancer
AB Gladden et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models
S Yakar et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
The insulin-like growth factor-1 receptor as a target for cancer therapy
R Baserga
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer
F Hofmann et al.
DRUG DISCOVERY TODAY (2005)
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
CS Mitsiades et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2005)
Cooperation of amphiregulin and insulin-like growth factor-1 inhibits bax- and bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells
A Hurbin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts
L Goetsch et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
A Camirand et al.
BREAST CANCER RESEARCH (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Insulin-like growth factors and neoplasia
MN Pollak et al.
NATURE REVIEWS CANCER (2004)
Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
HE Jones et al.
ENDOCRINE-RELATED CANCER (2004)
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225):: Superiority over single-agent receptor targeting
P Matar et al.
CLINICAL CANCER RESEARCH (2004)
Understanding p27kip1 Deregulation in Cancer Downregulation or Mislocalization?
Giuseppe Viglietto et al.
CELL CYCLE (2002)
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor
AP Gilmore et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake
AL Edinger et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
p27Kip1:: Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer
J Philipp-Staheli et al.
EXPERIMENTAL CELL RESEARCH (2001)
Transactivation of the EGF receptor mediates IGF-1-stimulated Shc phosphorylation and ERK1/2 activation in COS-7 cells
FL Roudabush et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
